ADMS News and Press, Adamas Pharmaceuticals Inc. From 12/06/19

Adamas Pharmaceuticals ( ADMS ) has taken numerous steps to proliferate GOCOVRI adoption and the numbers are slowly grinding higher. The company’s third-quarter product sales came in a $13.9M, which was a 9% increase over Q2 and a 31% increase over Q3 of last year. Thus far, GOCOVRI h...

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with this Read more ...

Gainers: HQY   +11.9% . RAPT   +8.2% . CIH   +8.2% . SIGA   +5.0% . NPO   +4.8% . More news on: HealthEquity, Inc., RAPT Therapeutics, Inc., China Index Holdings Limited, Stocks on the move, Read more ...

EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive...

Adamas Pharmaceuticals, Inc. (ADMS) Q3 2019 Earnings Conference Call November 07, 2019, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Neil McFarlane - CEO & Director Vijay Shreedhar - Chief Commercial Officer Rajiv Patni - Chief Medical Officer Christophe...

The following healthcare companies have file for mixed shelf offerings: More news on: Adamas Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Adamas Pharma (NASDAQ: ADMS ): Q3 GAAP EPS of -$0.99 misses by $0.11 . Revenue of $13.9M (+31.0% Y/Y) misses by $0.17M . Shares -4.3% . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

- Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019 EMERYV...

EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close. Subsequently, Adamas’ management team will host a con...

Noteworthy events during the week of October 27 - November 2 for healthcare investors. More news on: AMAG Pharmaceuticals, Inc., Agile Therapeutics, Inc., Adamas Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...